Table 2 Baseline characteristics of included studies
From: Efficacy and safety of carbon ion radiotherapy for chordomas: a systematic review and meta-analysis
Study | Institution | Study type | Outcomes | Period | No. of patients | Median age (year) | Male/female | Median follow-up (month) |
|---|---|---|---|---|---|---|---|---|
Mizoe 2009 [15] | Japan (NIRS) | phase I/II or II | Survival, toxicity | 1995–2007 | 33 | 47 (16–76) | 14/19 | 53 (8–129) |
Imai 2011 [16] | Japan (NIRS) | retrospective | Survival, toxicity | 1996–2007 | 95 | 66 (30–85) | 68/27 | 42 (13–112) |
Imai 2016 [17] | Japan (NIRS) | retrospective | Survival, toxicity | 1996–2013 | 188 | 66 (26–87) | 128/60 | 62 (6.8–147.5) |
Koto 2020 [18] | Japan (NIRS) | retrospective | Survival, toxicity | 2002–2016 | 34 | 52 (16–76) | 18/16 | 108 (9–175) |
Demizu 2021 [19] | Japan (Multicentre)* | retrospective | Survival, toxicity | 2003–2014 | 219 | 67 (26–87) | 151/68 | 56 (7–132) |
§Shiba 2021 [20] | Japan (GHMC) | prospective | Survival, toxicity | 2011–2019 | 32 | 67 (27–84) | 24/8 | 36.9 (4.4–96.4) |
Aoki 2022 [21] | Japan (NIRS) | retrospective | Survival, toxicity | 2005–2014 | 19 | 63 (26–81) | 6/13 | 68 (29–144) |
Evangelisti 2019 [22] | Italy (CNAO) | prospective | Survival, toxicity | 2013–2016 | 18 | 64.7 (38–83) | 12/6 | 23.3 (6–47) |
†Iannalfi 2020 [23] | Italy (CNAO) | prospective | Survival, toxicity | 2011–2018 | 65 | 58 (13–81) | 42/23 | 49 (6–87) |
Uhl 2014 [24] | Germany (HIT) | retrospective | Survival, toxicity | 1998–2008 | 155 | 48(15–85) | 76/79 | 72(12–165) |
†Mattke 2023 [25] | Germany (HIT) | retrospective | Survival, toxicity | 2009–2014 | 111 | 51 | 63/48 | 52.2 |